BDTX | Black Diamond Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.25 - 5.59
52 Week Range	1.6200 - 7.66
Beta	3.31
Implied Volatility	306.41%
IV Rank	92.85%
Day's Volume	492,872
Average Volume	664,146
Shares Outstanding	56,504,900
Market Cap	305,126,460
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-01-31

Valuation
Profitability
Growth
Health
P/E Ratio	-3.60
Forward P/E Ratio	-0.95
EPS	-1.50
1YR Price Target	3.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	54
Country	USA
Website	BDTX

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535.

BDTX's peers: ABEO, ACIU, ADAP, ADCT, AGIO, AKRO, ALEC, ALVR, ALXO, ARCT, ARVN, PASG, TCRR, HARP, RVMD, BCEL, STOK, FIXX, CABA, CRNX, CYTK, DARE, DNLI, DTIL, ERAS, ETON, EWTX, FDMT, GOSS, IGMS, NKTX, NRIX, PLRX, PRLD, PTGX, QSI, RAPT, RLAY, RNA, RYTM, SAGE, SLDB, SRRK, SWTX, SYRS, TCRT, TNGX, YMAB, IVVD, PROK

*Chart delayed

Analyzing fundamentals for BDTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see BDTX Fundamentals page.

Watching at BDTX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on BDTX Technicals page.